nach oben

Investigational New Drugs

Erschienen in:

16.11.2023 | Review

Immunoneoadjuvant therapy with immune checkpoint inhibitors of gastric cancer: an emerging exemplification

Immunoneoadjuvant therapy of gastric cancer

verfasst von: Guoliang Yao, Jianyong Yuan, Qianqian Duan, Yuan Tan, Qin Zhang, Dongsheng Chen, Jingbo Chen

Erschienen in: Investigational New Drugs | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Summary

Advances in immune checkpoint inhibitors (ICIs) have enabled more effective treatment for individuals with various types of solid tumors. Given the improved survival benefit and acceptable safety profile of ICIs in advanced gastric cancer, there is plenty of interest in the use of ICIs in the neoadjuvant setting with curative intent. Theoretically, immunoneoadjuvant with ICIs could boost the levels of endogenous tumor antigen present in the tumor to enhance T-cell priming and further enhance systemic immunity. This systemic immune response may improve the detection and elimination of the disseminated micrometastatic tumors beyond the resected tumor, which are sources of postsurgical relapse. Numerous clinical studies have begun to explore the application of ICIs in neoadjuvant treatment of gastric cancer. This article reviews the progress in the use of ICI monotherapy and in combination with alternative therapies for the treatment of gastric cancer to aid in the development of gastric cancer immunoneoadjuvant therapy and improve the overall therapeutic benefit.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 71(3):209–249CrossRefPubMed

Dolcetti R, De Re V,Canzonieri V (2018) Immunotherapy for Gastric Cancer: Time for a Personalized Approach? Int J Mol Sci 19(6)

Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F (2020) Gastric cancer. Lancet. 396(10251):635–648CrossRefPubMed

Ajani JA, D'Amico TA, Almhanna K, Bentrem DJ, Chao J, Das P et al (2016) Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 14(10):1286-1312

Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD et al (2015) PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 372(26):2509–20CrossRefPubMedPubMedCentral

Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK et al (2017) Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 357(6349):409–413ADSCrossRefPubMedPubMedCentral

Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP et al (2020) Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 38(1):1–10CrossRefPubMed

Oaknin A, Gilbert L, Tinker A V, Brown J, Mathews C, Press J et al (2022) Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study. J Immunother Cancer 10(1)

Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L et al (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 398(10294):27–40CrossRefPubMedPubMedCentral

10.

Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C et al (2022) Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 20(2):167-192

11.

Smyth EC, Wotherspoon A, Peckitt C, Gonzalez D, Hulkki-Wilson S, Eltahir Z et al (2017) Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. JAMA Oncol. 3(9):1197–1203CrossRefPubMed

12.

Sun J, Wang X, Zhang Z, Zeng Z, Ouyang S, Kang W (2021) The Sensitivity Prediction of Neoadjuvant Chemotherapy for Gastric Cancer. Front Oncol. 11:641304CrossRefPubMedPubMedCentral

13.

Yu Y, Ma X, Zhang Y, Zhang Y, Ying J, Zhang W et al (2019) Changes in Expression of Multiple Checkpoint Molecules and Infiltration of Tumor Immune Cells after Neoadjuvant Chemotherapy in Gastric Cancer. J Cancer. 10(12):2754–2763CrossRefPubMedPubMedCentral

14.

Topalian SL, Taube JM, Pardoll DM (2020) Neoadjuvant checkpoint blockade for cancer immunotherapy. Science 367(6477)

15.

Hasegawa H, Shitara K, Takiguchi S, Takiguchi N, Ito S, Kochi M et al (2022) A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer. Gastric Cancer. 25(3):619–628CrossRefPubMedPubMedCentral

16.

Emens LA, Middleton G (2015) The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 3(5):436–43CrossRefPubMedPubMedCentral

17.

McLaughlin M, Patin EC, Pedersen M, Wilkins A, Dillon MT, Melcher AA et al (2020) Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nat Rev Cancer. 20(4):203–217CrossRefPubMed

18.

Jiang H, Yu X, Li N, Kong M, Ma Z, Zhou D et al (2022) Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study. J Immunother Cancer 10(3)

19.

Li S, Yu W, Xie F, Luo H, Liu Z, Lv W et al (2023) Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer. Nat Commun. 14(1):8ADSCrossRefPubMedPubMedCentral

20.

Wei J, Lu X, Liu Q, Fu Y, Liu S, Li L et al (2022) Efficacy and Safety of Sintilimab in Combination with Concurrent Chemoradiotherapy for Locally Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (SHARED): Study Protocol of a Prospective, Multi-Center, Single-Arm Phase 2 Trial. Cancer Manag Res. 14:2007–2015CrossRefPubMedPubMedCentral

21.

Li S, Xu Q, Dai X, Zhang X, Huang M, Huang K et al (2022) Efficacy and toxicity of neoadjuvant immune checkpoint inhibitors in resectable gastric cancer: A meta-analysis and systematic review. 40(4_suppl):291-291

22.

Guo H, Ding P, Sun C, Yang P, Tian Y, Liu Y et al (2022) Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial. Front Oncol. 12:927781CrossRefPubMedPubMedCentral

23.

Wei J, Lu X, Liu Q, Fu Y, Liu S, Yang J et al (2021) SHARED: Efficacy and safety of sintilimab in combination with concurrent chemoradiotherapy (cCRT) in patients with locally advanced gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma. 39(15_suppl):4040-4040

24.

Wei J, Liu Q, Chen H, Zhang X, Zhao F, Fu Y et al (2022) Abstract 6176: CD56 dim+ immune infiltration and reprogrammed TMEs associated with response to neoadjuvant anti-PD-1 immunotherapy plus concurrent chemoradiotherapy in locally advanced gastric or gastroesophageal junction adenocarcinoma. Cancer Res 82(12_Supplement):6176-6176

25.

Raufi AG, Lee S, May M, Portillo AD, Sender N, Ana SS et al (2022) Abstract CT009: Phase II trial of perioperative pembrolizumab plus capecitabine and oxaliplatin followed by adjuvant pembrolizumab for resectable gastric and gastroesophageal junction (GC/GEJ) adenocarcinoma. Cancer Res 82(12_Supplement):CT009-CT009

26.

Tang ZQ, Wang Y, Liu D, Yu YY, Cui YH, Tang C et al (2021) 1385P Phase II study of neoadjuvant camrelizumab combined with chemoradiation for locally advanced proximal gastric cancer (Neo-PLANET, NCT03631615). Annals of Oncology. 32:S1049CrossRef

27.

Tang Z, Wang Y, Liu D, Wang X, Xu C, Yu Y et al (2022) The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction. Nat Commun. 13(1):6807ADSCrossRefPubMedPubMedCentral

28.

Ludford K, Raghav KPS, Murphy MAB, Fleming ND, Nelson DA, Lee MS et al (2021) Safety and efficacy of neoadjuvant pembrolizumab in mismatch repair deficient localized/locally advanced solid tumors. 39(15_suppl):2520-2520

29.

Ludford K, Ho WJ, Thomas JV, Raghav KPS, Murphy MB, Fleming ND et al (2023) Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors. J Clin Oncol. 41(12):2181–2190CrossRefPubMed

30.

André T, Tougeron D, Piessen G, de la Fouchardière C, Louvet C, Adenis A et al (2023) Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study. J Clin Oncol. 41(2):255–265CrossRefPubMed

31.

Li S, Yu W, Xie F, Liu Z, Lv W, Shi D et al (2021) A prospective, phase II, single-arm study of neoadjuvant/conversion therapy with camrelizumab, apatinib, S-1 ± oxaliplatin for locally advanced cT4a/bN+ gastric cancer. 39(15_suppl):4061-4061

32.

Kennedy T, Shah MM, In H, Chuy JW, Moore DF, Kooby DA et al (2021) Preoperative pembrolizumab for MSI high, EBV positive or PD-L1 positive locally advanced gastric cancer followed by surgery and adjuvant chemoradiation with pembrolizumab: Interim results of a phase 2 multi-center trial (NCT03257163). 39(15_suppl):e16111-e16111

33.

Liu Y, Han G, Li H, Zhao Y, Zhuang J, Wang G et al (2020) Camrelizumab combined with FOLFOX as neoadjuvant therapy for resectable locally advanced gastric and gastroesophageal junction adenocarcinoma. 38(15_suppl):4536-4536

34.

Tao K, Yin Y, Lin Y, Li W, Li R, Liu W et al (2022) Neoadjuvant PD-1 inhibitor tislelizumab combined with s-1 plus oxaliplatin in patients with local advanced gastric cancer or gastroesophageal junction adenocarcinoma: Interim results of a single-arm, phase II trial. 2022; 40(4_suppl):300–300

35.

Yin Y, Lin Y, Yang M, Lv J, Liu J, Wu K et al (2022) Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results of a phase 2, single-arm trial. Front Oncol. 12:959295CrossRefPubMedPubMedCentral

36.

Sun W, Saeed A, Al-Rajabi RMDT, Kasi A, Veeramachaneni NK, Al-Kasspooles MF et al (2022) A phase II study of perioperative mFOLFOX plus pembrolizumab combination in patients with potentially resectable adenocarcinoma of the esophageal, gastroesophageal junction (GEJ) and stomach. 2022; 40(16_suppl):4047–4047

37.

Comprehensive molecular characterization of gastric adenocarcinoma (2014) Nature. 513(7517):202–9CrossRef

38.

Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS et al (2015) Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 21(5):449–56CrossRefPubMed

39.

Kim ST, Cristescu R, Bass AJ, Kim KM, Odegaard JI, Kim K et al (2018) Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 24(9):1449–1458CrossRefPubMed

40.

Ock CY, Hwang JE, Keam B, Kim SB, Shim JJ, Jang HJ et al (2017) Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. Nat Commun. 8(1):1050ADSCrossRefPubMedPubMedCentral

41.

Pietrantonio F, Miceli R, Raimondi A, Kim YW, Kang WK, Langley RE et al (2019) Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. J Clin Oncol. 37(35):3392–3400CrossRefPubMed

42.

Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 26:677–704CrossRefPubMedPubMedCentral

43.

Jardim DL, Goodman A, de Melo Gagliato D, Kurzrock R (2021) The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. Cancer Cell. 39(2):154–173CrossRefPubMed

44.

Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A et al (2019) Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 30(1):44–56CrossRefPubMed

45.

Lu S, Stein JE, Rimm DL, Wang DW, Bell JM, Johnson DB et al (2019) Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis. JAMA Oncol. 5(8):1195–1204CrossRefPubMedPubMedCentral

46.

Wang D, Hu X, Xiao L, Long G, Yao L, Wang Z et al (2021) Prognostic Nutritional Index and Systemic Immune-Inflammation Index Predict the Prognosis of Patients with HCC. J Gastrointest Surg. 25(2):421–427CrossRefPubMed

47.

Fornarini G, Rebuzzi SE, Banna GL, Calabrò F, Scandurra G, De Giorgi U et al (2021) Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort. ESMO Open. 6(3):100118CrossRefPubMedPubMedCentral

48.

Raja R, Kuziora M, Brohawn PZ, Higgs BW, Gupta A, Dennis PA et al (2018) Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab. Clin Cancer Res. 24(24):6212–6222CrossRefPubMed

49.

Ricciuti B, Jones G, Severgnini M, Alessi JV, Recondo G, Lawrence M et al (2021) Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC). J Immunother Cancer 9(3)

50.

Taube JM, Akturk G, Angelo M, Engle EL, Gnjatic S, Greenbaum S et al (2020) The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation. J Immunother Cancer 8(1)

51.

Masuzawa T, Fujiwara Y, Okada K, Nakamura A, Takiguchi S, Nakajima K et al (2012) Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer. Int J Oncol. 41(4):1297–304CrossRefPubMed

52.

Curti BD, Kovacsovics-Bankowski M, Morris N, Walker E, Chisholm L, Floyd K et al (2013) OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res. 73(24):7189–7198CrossRefPubMedPubMedCentral

Titel: Immunoneoadjuvant therapy with immune checkpoint inhibitors of gastric cancer: an emerging exemplification
Immunoneoadjuvant therapy of gastric cancer
verfasst von: Guoliang Yao
Jianyong Yuan
Qianqian Duan
Yuan Tan
Qin Zhang
Dongsheng Chen
Jingbo Chen
Publikationsdatum: 16.11.2023
Verlag: Springer US
Erschienen in: Investigational New Drugs / Ausgabe 1/2024
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-023-01406-y

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Immunoneoadjuvant therapy with immune checkpoint inhibitors of gastric cancer: an emerging exemplification

Immunoneoadjuvant therapy of gastric cancer

Summary

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2024

RPTOR mutation: a novel predictor of efficacious immunotherapy in melanoma

Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis

Targeted delivery of liposomal Ribociclib to SLC7A5 transporters in breast cancer cells

CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial

Endosomal recycling inhibitors downregulate the androgen receptor and synergise with enzalutamide

Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie